Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.50 |
| ▸ | METAP1 | P53582 | 5/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BHMT | Q93088 | 1/20 | 0.35 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18090960 | 0.82 | TSHR (0.43) | METAP2METAP1RNPEPANPEPTSHR | |
| SCHEMBL28513010 | 0.82 | TSHR (0.43) | METAP2METAP1RNPEPANPEPTSHR | |
| SCHEMBL18090982 | 0.82 | TSHR (0.43) | METAP2METAP1RNPEPANPEPTSHR | |
| Cadaverine Tartrate SCHEMBL28729564 | 0.82 | BHMT (0.50) | RNPEPBHMTBHMT2 | |
| Cadaverine Tartrate SCHEMBL28729563 | 0.82 | BHMT (0.50) | RNPEPBHMTBHMT2 | |
| Hydrochloric Acid SCHEMBL28497859 | 0.80 | TSHR (0.41) | METAP2METAP1RNPEPTSHR | |
| Hydrochloric Acid SCHEMBL28497858 | 0.80 | TSHR (0.41) | METAP2METAP1RNPEPTSHR | |
| Hydrochloric Acid SCHEMBL28511725 | 0.80 | TSHR (0.41) | METAP2METAP1RNPEPTSHR | |
| SCHEMBL5849991 | 0.80 | METAP2 (0.56) | METAP2METAP1BHMTBHMT2 | |
| SCHEMBL5848419 | 0.80 | METAP2 (0.57) | METAP2METAP1TSHRBHMTBHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | claimed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | claimed |
| WO-2014169026-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2011150022-A2 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-7030262-B2 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1546087-A1 | 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS | Abbott Laboratories (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004013085-A1 | 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS | ABBOTT LABORATORIES (US) | 2004-02-12 | — | — | WO | disclosed |
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | disclosed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | HDGF, HCAR2, HCAR3 | METAP2 473/4885METAP1 248/4885RNPEP 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.